A Simple Approach for Measuring FRET in Fluorescent Biosensors Using Two-photon Microscopy

Richard N. Day¹*, Wen Tao², Kenneth W. Dunn²

¹ Department of Cellular and Integrative Physiology; Indiana University School of Medicine; 635 Barnhill Dr., Indianapolis, IN USA

² Department of Medicine; Division of Nephrology; Indiana University Medical Center; Indianapolis, IN USA

* Correspondence should be addressed to RND.

Voice: (317) 274-2166

Email: rnday@iupui.edu

DOI: nprot.2016.121

Figures: 6
Tables: 2
Boxes: 1
CFI: none
SI: Supplementary Sequence Archive

Editorial summary: This Protocol describes a simple pipeline for imaging FRET biosensor probes with two photon laser scanning microscopy (TPLSM). Validated FRET standards are described that can be used with any TPLSM setup to ensure sensitive detection of FRET ratios.

This is the author's manuscript of the article published in final edited form as:
Proposed Tweet: #NewNProt: Simplified use of #FRETbiosensor probes in #TwoPhotonMicroscopy [LINK] #TPLSM #FRET

Proposed Ontology

Biological sciences / Biological techniques / Optical spectroscopy / Fluorescence resonance energy transfer

Biological sciences / Biophysics / Biological fluorescence

Biological sciences / Cell biology / Cell signalling

Biological sciences / Biological techniques / Microscopy / Multiphoton microscopy

Biological sciences / Biological techniques / Sensors and probes

Keywords: two photon laser-scanning microscopy, TPLSM, Förster resonance energy transfer, FRET, fluorescent protein, biosensor probe, PKA activity

Supporting primary paper:


Permissions required for:

Figures 3, 4, 5 and 6.
ABSTRACT

Genetically encoded fluorescent protein (FP)-based biosensor probes are useful tools for monitoring cellular events in living cells and tissues. Because these probes were developed for one-photon excitation approaches, their broad two-photon excitation (2PE) and poorly understood photo-bleaching characteristics have made their implementation in studies using two-photon laser-scanning microscopy (TPLSM) challenging. Here, we describe a protocol that simplifies the use of Förster Resonance Energy Transfer (FRET)-based biosensors in TPLSM. First, the TPLSM system is evaluated and optimized using FRET standards expressed in living cells, which enables the determination of spectral bleedthrough and the confirmation of FRET measurements from the known standards. Then, we describe how to apply the approach experimentally using a modified version of the AKAR protein kinase A (PKA) biosensor as an example, first in cells in culture, and then in hepatocytes in the liver of living mice. The microscopic imaging can be accomplished in a day in laboratories that routinely use TPLSM.
INTRODUCTION

The use of TPLSM imaging to monitor the signals from biosensor proteins in living animals is of interest to many laboratories because it allows noninvasive detection of spatial and temporal characteristics of specific cell signaling or metabolic events. These genetically encoded biosensor proteins contain reporter modules that typically consist of fluorescent proteins (FPs) directly linked to sensing units that detect specific cellular events\(^1\). Many biosensor probes rely on Förster resonance energy transfer (FRET) to report the changes in protein conformation that occur in response to the cellular event\(^1-6\). There are, however, significant challenges to the use of TPLSM to detect the FRET signals from biosensor probes in intact tissues, which fall into three general categories: 1) issues related to the two-photon excitation (2PE) characteristics of the biosensor probes, 2) difficulties in expressing the genetically encoded biosensors in the desired cell-type in living animals, and 3) problems associated with conducting high-resolution microscopy in living animals. These three challenges are discussed further below, but this Protocol specifically addresses the first issue: identification, characterization, and validation of a FRET-based FP biosensor suitable for TPLSM in intact tissues.

1) Optimized probes for TPLSM. Many existing biosensor probes that were developed for one-photon excitation may perform poorly (or not at all) under 2PE. Even those probes that perform well under 2PE may not be efficiently excited by the narrow range of wavelengths accessible with the titanium sapphire lasers used in most TPLSM systems (tunable from 690 to 1040 nm, but peaking between 750 and 850 nm). Many biosensor assays are based upon ratiometric measurements of images collected using two different excitation wavelengths. This complicates measurements by TPLSM because most FPs have broad two-photon cross-sections,
limiting the ability to selectively excite one or the other FP. Furthermore, most TPLSM systems are equipped with a single infrared laser, so the collection of ratiometric FRET measurements may require re-tuning of the laser between image acquisitions; a process that is slow (precluding dynamic studies), and introduces measurement errors because of changes in laser alignment. Finally, photobleaching processes that occur under 2PE are poorly understood. Unlike single-photon excitation, the rate of photobleaching under 2PE increases exponentially with illumination power, sometimes increasing with the 3rd or 4th power of the illumination level\textsuperscript{7,8}. Since differences in the susceptibility of the donor- and acceptor-FPs to photobleaching could affect ratiometric measurements, it is particularly important to use FPs that are photo-stable and free from photo-switching behavior.

2) In vivo expression of FP biosensors. The sequences that encode the biosensor probes are easily incorporated into plasmid or viral vectors that allow their transfer into living cells or organisms. The use of suitable cell-type specific promoters can restrict the expression of the biosensors to specific tissues, and the probes can be directed to specific subcellular organelles by incorporating suitable targeting sequences. The fluorescence signals from biosensor probes have been successfully imaged in a wide variety of organisms. For example, transgenic \textit{C. elegans}, \textit{Drosophila}, and Zebrafish have been generated that express calcium sensing biosensor proteins\textsuperscript{9-11}. In general, the imaging of biosensor activities in transgenic mice, however, has proven to be more difficult\textsuperscript{12}. A problem often encountered with transgenes stably integrated in mice is low-level expression resulting from transgene silencing or recombination events that occur between the highly homologous sequences encoding the sensor FPs\textsuperscript{13,14}. Transgenic mice generated by transposon-mediated gene transfer methods have been reported to have higher levels of biosensor expression\textsuperscript{13-15}. Transgenic biosensor mice that express a variety of different
probes, including sensors of chloride\textsuperscript{16}, calcium\textsuperscript{17,18}, and voltage\textsuperscript{19}, are available commercially (The Jackson Laboratory, Bar Harbor, ME) and might be useful for specific intravital imaging applications. Transgenic mice expressing fluorescent biosensors for PKA, Erk, Rac, Ras are also available from the National Institutes of Biomedical Innovation, Health and Nutrition (Osaka, Japan). Further, there are published studies reporting transgenic biosensor mice with ubiquitous tissue distribution\textsuperscript{13,19}, or restricted tissue expression\textsuperscript{12}. The critical question for investigators is whether the biosensor expression is sufficiently high in the desired tissue in a particular mouse model to obtain unambiguous measurements of changing cell signaling events\textsuperscript{12}.

Viral transduction is an alternative approach that offers rapid biosensor probe expression in living animals without the need for lengthy breeding strategies to achieve stable expression. The challenge for in vivo administration of viral vectors, however, is to obtain expression of the biosensor probes in the relevant cell types. The expression of probes in a particular tissue can be achieved using cell-type specific promoters that restrict the biosensor expression to the target cells. However, if the cells of interest can be identified based on morphology, it might not be necessary to achieve selective expression in specific cell populations. Further, the systemic administration of unmodified adenovirus (Ad) generally results in the accumulation of the transgene in the liver and spleen\textsuperscript{20}, so the tropism to these organs can be exploited for imaging studies.

3) High resolution microscopy in living animals. Intact, living organisms present unique challenges for microscopy. First, the physiological welfare of the animal must be maintained and continuously monitored while the animal is on the microscope stage. Second, in most cases, the tissue of interest must be surgically exposed, requiring the development of methods
for anesthesia and delicate surgery. Third, the tissue must be immobilized so that motion induced by respiration and the heartbeat is reduced to sub-micron levels.

The solutions to these challenges vary depending on the equipment used and the particular organ to be imaged. In our studies of kidney and liver\textsuperscript{21-24}, an inverted microscope stand is used to image the surgically exposed organs that are secured to a glass-bottomed dish (see Figure 1). The anesthetized animal is placed on the microscope stage, and the animal’s temperature is maintained using a heating pad and monitored using a rectal thermometer. Generally, tissue motion can be minimized by careful placement of the tissue, and can be reduced further by bonding small regions of the tissue to the coverglass with cyanoacrylate adhesive. Additionally, gating the image collection to respiration can minimize the motion artifacts in tissues such as the lung\textsuperscript{25,26}. Finally, motion-induced distortions can be eliminated from the collected images using various methods of digital image analysis\textsuperscript{27-31}.

Quantitative intravital microscopy is also complicated by the inevitable loss of signal that occurs when imaging into highly scattering biological tissues. Therefore, the intensity measurements obtained from different depths cannot be directly compared. In this regard, using FRET-based biosensors can be advantageous. The ratio images obtained from biosensors will be minimally affected by depth provided that the scattering and absorption does not vary significantly for the emission wavelengths of the probe. While we find no evidence of a significant effect of depth on FRET measurements obtained in vivo, minor effects were observed in other studies\textsuperscript{32}. Therefore, biosensor measurements collected over a large range of depths should be evaluated for systematic effects of depth on the FRET ratio. In general, the effects of depth on ratiometric measures can be minimized by using non-descanned detectors
that are less susceptible to the effects of light scatter, and by avoiding FPs with widely different emission spectra.

Development of the Protocol

Previously, we described the characterization of FPs for FRET biosensor probes specifically intended for intravital imaging using TPLSM. Since the cyan FPs (CFP) are optimally excited close to the power maximum of the titanium-sapphire lasers used in most TPLSM systems, we focused our evaluations of potential FRET donors on the newer variants of the CFPs that have improved brightness and photostability, and no photo-switching behavior. Based on previous studies demonstrating that wavelengths near 800 nm could be used for relatively selective excitation of CFP over YFP, we focused our evaluations of potential FRET acceptors on newer, improved variants of YFP. Based on these studies, we identified monomeric (m)Turquoise and mVenus as optimal FPs for TPLSM. We found that illumination at 810 nm efficiently excited mTurquoise with minimal direct excitation of mVenus. The selective excitation of mTurquoise at 810 nm allows ratiometric FRET measurements in vivo using TPLSM at a single excitation wavelength. Moreover, the use of the cyan and yellow FPs is compatible with most TPLSM configurations.

A critical step in the acquisition of measurements from FRET-based biosensors is validation of the sensitivity of the method. It is necessary to demonstrate that measurements of subtle changes in the FRET ratio truly reflect the responses of the biosensor to cellular events. In general, FRET measurements should be reproduced using multiple methods. For example, FRET estimates based on measurements of sensitized emission should be complemented with estimates from acceptor photobleaching or fluorescence lifetime measurements. Given the
inherent challenges of intravital microscopy our goal was to develop a protocol that would minimize the validation studies that must be conducted. We accomplish this by providing a set of completely validated FRET standards, and a simple method by which the end-user can characterize and optimize FRET measurements in their own systems.

Overview of the Procedure

Here, we describe a protocol in which a TPLSM system can be optimized and validated for FRET measurements in studies of cultured cells, prior to studies in living animals (see Figure 2). We demonstrate intravital FRET biosensor imaging using an A kinase activity reporter (AKAR) biosensor of PKA activity, expressed by adenoviral transduction of the mouse liver. Our approach to intravital measurements of FRET-biosensor activity involves four stages: (i) characterization of the emission spectra and the determination of spectral crosstalk correction factors for the donor and emission FPs in the user’s system; (ii) validating the experimental system for measuring FRET using FRET standards expressed in cells in culture; (iii) validation of the FRET-biosensor for measurements from cells in culture; (iv) measurement of FRET-biosensor responses in cells in living animals.

Measurement of spectral crosstalk correction factors. The imaging protocol described here exploits the relatively selective 2PE of mTurquoise\textsuperscript{35} over mVenus\textsuperscript{40} using illumination at 810 nm, which enables the measurement of FRET ratios from single, two-channel images (Figure 3). The accurate measurement of FRET efficiencies (\(E_{\text{FRET}}\)), however, requires the application of correction factors for spectral crosstalk (Box 1). These correction factors are entirely dependent upon the configuration and performance of the microscope system, and must be measured for each system.
Characterization and validation of FRET measurements using FRET standards. The FRET standards are critical tools for verifying both the biological model and for optimizing the particular imaging system used for FRET measurements. By providing a range of calibrated, reproducible $E_{\text{FRET}}$, the FRET standards allow the user to evaluate the performance of the system for the detection of FRET, and importantly, allow an assessment of the sensitivity of the measurements (described in Anticipated Results). We have developed plasmids for a set of fully validated FRET standards, based upon mTurquoise and mVenus (see Figure 2, sequence information is provided in the Supplementary Sequence Archive, plasmids available from authors on request). Measurements of $E_{\text{FRET}}$ obtained from living cells expressing these standards (using the approach described in Box 1) are used to validate and optimize the user’s system for detection of FRET in mTurquoise-mVenus-based biosensors.

Validation of the FRET biosensor probe activity in cultured cells. To verify and fully characterize the performance of the FRET biosensor in the user’s system, preliminary studies are conducted in cultured cells, which can be manipulated to identify the full range of FRET ratios provided by the biosensor under physiological conditions. Here, an AKAR biosensor with a reporter module consisting of mTurquoise and circular permuted (cp)Venus FPs (AKAR4.1) is used to monitor PKA activity in living cells. The response of the AKAR4.1 probe expressed in cells treated with a specific PKA agonist is used to characterize the performance of the system for measurements of changing FRET ratios.

Measurements of biosensor probe activity in the living animal. Once the imaging system has been validated using the FRET standards, and the performance of the biosensor has been verified in living cells in culture, the final step is to apply the information collected in the in vitro studies to use the FRET probe to assay cellular function in the living animal. We use the
expression of Ad AKAR4.1 in the mouse liver to demonstrate the use of this protocol to measure the activity of the PKA pathway in vivo.

**Limitations of the approach**

The protocol described here is designed for compatibility with the commonly available commercial TPLSM systems equipped with a single Titanium-sapphire laser, and detection pathways compatible with the emission spectra of cyan and yellow FPs. We recognize that investigators may conduct their TPLSM studies on a shared instrument where the non-descanned detectors may not be configured for the efficient collection of cyan and yellow fluorescence. In this situation, it may be necessary to use the descanned detectors that are typically easier to configure. Since descanned detectors are located far from the back aperture of the objective, they collect less of the fluorescence scattered in the tissue, and thus provide poorer reach into biological tissues than non-descanned detectors located adjacent to the back aperture of the objective. The ideal design for a system dedicated to 2PE FRET studies would be one in which the non-descanned pathway was fitted with filters optimized for sensitive and specific detection of mTurquoise and mVenus.

In addition, the objective lenses used to obtain subcellular resolution provide a field of view that is typically less than a millimeter across. Therefore, it can be difficult to draw general conclusions about cellular function based upon observations collected within such a tiny window. More significantly, the microscope samples only the most superficial layers of biological tissues. Even TPLSM, which allows deeper imaging than confocal microscopy, is generally limited to depths of less than 100 microns into tissue. Thus, TPLSM is incapable of analyzing populations of cells located deep in organs (e.g., renal medulla) or to evaluate physiological properties below the surface of tumors.
Finally, the intravital setting presents significant challenges to the expression of fluorescent biosensor probes. Here, we use Ad transduction to achieve high level expression of a biosensor probe in the liver of mice. The Ad provides robust, but transient, expression of the transgenes. Further, there are typically inflammatory responses to the virus that can limit its use in prolonged studies. These problems are largely overcome by adeno-associated virus (AAV) or lentivirus vectors, which can achieve persistent transgene expression with minimal inflammatory responses. Importantly, there are many serotypes of AAV that differ in their capsid protein structures, and this enables distinct tissue tropism for the different serotypes\textsuperscript{20,41}.

**Advantages**

A crucial component of this protocol is the use of the well-characterized FRET standards as a tool to validate that both the experimental model and microscope system are optimized for sensitive measurements of FRET (see **Anticipated Results**). Therefore, it is necessary that the end user determines the corrected FRET efficiency for each of the standards to assess the performance of their system, and to compare their results with those obtained here (or from other studies if different standards are used). The measurement of the FRET standards on the microscope system enables confirmation of the ratiometric FRET measurements acquired in vivo using the single wavelength 2PE of the biosensor probes. The acquisition of single, two-channel images with TPLSM simplifies image collection, maximizing temporal resolution, and minimizing the number of in vivo studies. The use of a single wavelength for 2PE offers additional advantages for the measurement of biosensor probe activity in intact tissue, avoiding the delay in the collection of ratio images and the effects of shifts in laser alignment at different wavelengths.
Several groups have described the use of fluorescence lifetime imaging as an effective approach for measuring FRET in vivo\textsuperscript{42-44}. The ratiometric approach offers a few key advantages over fluorescence lifetime-based approaches. First, it is easily implemented in most TPLSM systems, requiring no additional instrumentation. Second, the ratiometric approach provides better temporal resolution; whereas fluorescence-lifetime measurements typically require image collection over tens of seconds, images for ratiometric measurements can be collected in less than a second.

We demonstrate the use of our approach to measure PKA activity in vivo. However, we emphasize that this approach should be generalizable to other FRET-based biosensors, once the reporter module is modified to include mTurquoise and suitable acceptor. For example, we have found very similar results using the optimized calcium biosensor probe, Twitch2b\textsuperscript{45}. Thus, with minimal effort the approach described here could be applied to many other biosensor probes by exchanging the earlier, more photo-labile, variants of the cyan FPs.

**MATERIALS**

**REAGENTS**

- Dulbecco’s Modified Eagle’s Medium (DMEM, Fisher Scientific Inc. Cat. # 50-188-267FP)
- Dulbecco’s Modified Eagle’s Medium without phenol red (Fisher Scientific Inc. Cat. # MT17205CV)
- Fetal bovine serum (FBS, Atlanta Biologicals. Cat. # S11150)
- Trypsin (Fisher Scientific Inc. Cat. # MT25-051-Cl, stored at -20° C).
- X-tremeGene HP DNA transfection reagent (Roche Diagnostics, Indianapolis, IN, Cat. #06366236001, made up fresh).

- Appropriate biosensor construct. In the Procedure, we use the Adenovirus (Ad) CMV-Turq-AKAR4 vector as an example, which was made as described previously\(^4^9\) (see Supplementary Sequence Archive).

- HEK-293 cells (ATCC CRL-1573) Caution! – HEK-293 cells contain Adenovirus 5 DNA integrated into chromosome 19 and must be handled at Biosafety level 2. The cell lines used in your research should be regularly checked to ensure they are authentic and are not infected with mycoplasma.

- FP constructs. See Table 1. All FP constructs described here are available through the National Institutes of Health O’Brien Center for Advanced Renal Microscopic Analysis at Indiana University School of Medicine. The plasmid sequences can be found in Supplementary Sequence Archive.

Table 1: FP constructs required in the Procedure.

<table>
<thead>
<tr>
<th>Plasmid construct</th>
<th>Purpose</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>mTurquoise N1</td>
<td>to determine donor spectral bleedthrough</td>
<td></td>
</tr>
<tr>
<td>mVenus N1</td>
<td>to determine acceptor spectral bleedthrough</td>
<td></td>
</tr>
<tr>
<td>Turquoise-TRAF-Venus (TTRAFV)</td>
<td>Serves as a low FRET standard and is used to determine fractional excitation of Venus.</td>
<td>Turquoise is separated from Venus by the TRAF2 sequence.(^4^6) Typical (E_{\text{FRET}}) is 5-10%.</td>
</tr>
<tr>
<td>Turquoise-10aa-Venus (T10V)</td>
<td>Serves as an intermediate FRET standard.</td>
<td>Turquoise is separated from Venus by the sequence “SGLRSPPVAT”. Typical $\text{EFRET}$ is 30-35%.</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Turquoise-5aa-Venus (T5V)</td>
<td>Serves as a high FRET standard.</td>
<td>Turquoise is separated from Venus by the sequence “SGLRS”. Typical FRET efficiency ($\text{EFRET}$) is 40-45%.</td>
</tr>
<tr>
<td>Turquoise AKAR4.1</td>
<td>Biosensor probe to detect protein kinase A activity.</td>
<td>The AKAR4 biosensor$^{48}$ with Turquoise as the donor fluorophore.</td>
</tr>
</tbody>
</table>

- **Mice:** **Caution!** – Any experiments involving live mice must conform to relevant Institutional and National regulations. All animal studies were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee and conform to the “Guide for the Care and Use of Laboratory Animals” published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996).

**EQUIPMENT**

- Laser scanning microscope compatible with two-photon excitation at 810 nm and two channel fluorescence detection in the approximate ranges of 454 – 494nm for detection of mTurquoise and 520 – 580nm for detection of mVenus. Our system is described in Equipment Setup.
• Image processing software capable of quantifying signal levels in user-identified regions of interest, such as ImageJ (https://imagej.nih.gov/ij/), Metamorph (https://www.moleculardevices.com/), or the microscope manufacturer’s software.

• A laser power meter to measure the power at the specimen plane (PM100D power meter, Thorlabs, Newton, NJ).

REAGENT SETUP

**HEK-293 cells:** Human embryonic kidney (HEK)-293 cells are maintained in monolayer culture in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% (vol/vol) fetal bovine serum (FBS) at 37°C in a 5% (vol/vol) CO₂ incubator, and harvested at 80% confluence by treatment with Trypsin. The pH indicator dye Phenol red may cause background signals during imaging. Therefore, prior to imaging the medium should be replaced with the same medium lacking the indicator.

EQUIPMENT SETUP

**Intravital microscope system.** In our lab, IVM is conducted as previously described²⁴ using a modified Olympus FV1000 spectral laser-scanning confocal microscope system, mounted on an Olympus IX81 stand, and modified for two-photon excitation. Near-infrared illumination, provided by a MaiTai HP Ti-sapphire laser (Spectra-Physics, Santa Clara, CA) is attenuated using a Pockels cell electro-optical attenuator (Conoptics Inc., Danbury, CT), and the beam is expanded via a Keplerian collimator/beam expander. Images are acquired using an Olympus 25X, NA 1.05 XLPN water immersion objective (see Figure 1). Fluorescence is collected using the Olympus FV1000 photomultiplier detectors on the descanned detection pathway. The
FV1000 spectral detection system (spectral grating) is used to collect spectral data and to select emission wavelengths optimized for each fluorescent protein. Laser power at the specimen plane is measured using a PM100D power meter, Thorlabs, Newton, NJ).

**PROCEDURE**

1| *Transfection of cells with mTurquoise and mVenus plasmids.* 18 – 24 h before transfection, plate cells HEK-293 cells in 500 µl complete growth medium at a density of 3.0 – 3.5 x10^5 cells/well in 4-well Lab-Tek II chambered coverglasses. Incubate cell cultures overnight in a 5% (vol/vol) CO₂ incubator. The cells should be 50 – 85% confluent at the time of transfection, and each transfection should be performed in duplicate.

2| Allow X-tremeGENE HP DNA Transfection Reagent, DNA and diluent (Opti-MEM. I Reduced Serum Medium or serum-free medium) to warm to room temperature (~ 21º C), and gently mix.

3| For each transfection, place 300 µl diluent in a sterile tube.

4| Add 3 µg of the appropriate plasmid DNA (see table below) to each transfection mix. Pipet gently to mix.

<table>
<thead>
<tr>
<th>Transfected plasmid(s)</th>
<th>Step at which transfection performed</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>mTurquoise</em></td>
<td>4</td>
<td>Determining optimal</td>
</tr>
<tr>
<td>Protein Configuration</td>
<td>_measurement</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>mVenus</td>
<td>4</td>
<td>Determining optimal settings for detection (step 11) and spectral bleedthrough (step 13)</td>
</tr>
<tr>
<td>mTurquoise + mVenus</td>
<td>4</td>
<td>Determining fractional excitation at 810nm (step 16) and EFRET (step 21)</td>
</tr>
<tr>
<td>Turquoise-TRAF-Venus (TTRAFV)</td>
<td>4</td>
<td>Determining fractional excitation at 810nm (step 16) and EFRET (step 21)</td>
</tr>
<tr>
<td>Turquoise-5aa-Venus (T5V)</td>
<td>4</td>
<td>Determining EFRET (step 21)</td>
</tr>
<tr>
<td>Turquoise-10aa-Venus (T10V)</td>
<td>4</td>
<td>Determining EFRET (step 21)</td>
</tr>
<tr>
<td>AKAR4.1 biosensor (or probe of interest)</td>
<td>4</td>
<td>Biosensor probe for measurement of PKA</td>
</tr>
</tbody>
</table>
Add 9 μl X-tremeGENE HP DNA Transfection Reagent to the diluted DNA. (3:1 ratio of reagent to DNA). Pipet gently to mix.

Incubate for 15 – 30 min at room temperature.

Add 75 μl of the appropriate transfection complex to cells in a drop-wise manner.

Gently shake chambered coverglass to ensure even distribution, and then incubate the cells at 37º C in a 5% (vol/vol) CO₂ for 24 – 48 h before imaging.

System evaluation and optimization – determine the spectral ranges for the detectors (1.5-2 hrs)

Prepare TPLSM system. At least 30 minutes prior to image acquisition, turn on the system according to the manufacturer instructions, to ensure that power and alignment are completely stabilized prior to image collection. Tune and align laser at 810 nm. **CRITICAL STEP**: Allow the laser to warm and stabilize for ~ 30 min before imaging to ensure the system is consistent for image collection.

Prepare to collect images for measurement of spectral bleedthrough (SBT). 24 - 48 h after transfection of cells with mTurquoise or mVenus (at step 4), transfer transfected cells (from step 8) into a medium suitable for maintaining physiological pH in air, or into a chamber capable of maintaining 5% (vol/vol) CO₂ environment. Mount cells in a stage incubator set to maintain cells at 37 degrees C.

Optimize the microscope settings for optimal detection of mTurquoise and mVenus emissions. Users with filter-based systems should follow Option A. Users with spectral
fluorescence detectors should follow Option B to determine the spectral range settings for the imaging system..

**CRITICAL STEP:** The SBT components that contaminate the FRET signal result from the donor (mTurquoise) emission that bleeds into the acceptor detection channel (DSBT), and the direct excitation of the acceptor (mVenus) at the donor excitation wavelength (ASBT). It is necessary to correct for SBT in order to accurately determine FRET efficiency. The SBT corrections are specific to each microscope system, and are entirely dependent on spectral or filter settings on the microscope, so it is critical to always verify these settings on multi-user microscope systems.

(A) **Verification of the set-up of filter-based systems**

(i) Select the correct emission filters for the cyan and yellow channels, and the appropriate dichroic mirror.

(ii) Measure the signal from the cells expressing mTurquoise only and from cells expressing mVenus only (from step 8) to verify that the correct emission filters and dichroic mirrors are being used.

(B) **Optimizing systems with spectral fluorescence detectors**

(i) Using cultured cells expressing mTurquoise only and cells expressing mVenus only (from step 8), set the illumination to 810 nm, adjust illumination levels to fill the dynamic range of the detectors without saturation and collect emission scans from approximately 420 – 600 nm.
(ii) Evaluate the emission spectra of mTurquoise and mVenus and identify the optimal wavelength ranges for selectively detecting mTurquoise and mVenus fluorescence emissions. For our system, these ranges were determined to be 454–494 for detection of mTurquoise and 520–580 for detection of mVenus (Figure 1).

System evaluation and optimization – spectral bleedthrough and fractional excitation (1.5-2 hrs)

**CRITICAL:** This protocol uses a single excitation wavelength (810 nm) to measure FRET standard and biosensor activity. The FRET standards are used for system validation, so it is necessary to determine the corrected $E_{FRET}$ for each standard excited at this wavelength (Step 21). This requires the measurement and removal of the DSBT and ASBT (steps 13 and 16 and Box 1). Since a single excitation wavelength is used, the determination of the ASBT also requires the estimation of the fractional excitation of Venus at 810 nm. This is accomplished by measuring the average $I_{\text{Ch2-810}}/I_{\text{Ch2-960}}$ ratio from cells expressing a mixture of mTurquoise and mVenus (mTurquoise + mVenus), and the low FRET standard (Turquoise-TRAF-Venus, Step 16).

12| *Collect images for measurement of SBT* - Designate 810 nm as the illumination wavelength and select the optical configuration of the microscope system for optimal collection of CFP and YFP (determined in step 11A for users with filter-based systems) or set optical configuration according to the results obtained in step 11B (for users with spectral detection systems). Adjust laser power to fill the dynamic range of the detectors
without saturation. Collect two-channel images from living cells expressing 
mTurquoise only and from cells expressing mVenus only (from step 8).

13| *Image analysis for measurement of SBT.* Using image-processing software (e.g., 
ImageJ, Metamorph, or the microscope manufacturer’s software, identify regions-of-
interest in several cells expressing mVenus only and for each region measure the signal 
levels in the CFP and YFP channels. Correct these measurements for background by 
subtracting measurements obtained from nearby regions lacking fluorescence. For each 
cell, measure ASBT as the ratio of corrected measures obtained in the CFP channel to 
those obtained in the YFP channel. ASBT measurements are used to derive the 
correction factor A (Box 1), which is defined as the fraction of the signal in the acceptor 
channel that results from the direct excitation of mVenus at 810 nm.  

14| Using image-processing software, identify regions-of-interest in several cells expressing 
mTurquoise only. For each region measure the signal levels in the CFP and YFP 
channels. The images are corrected for background by subtracting measurements 
obtained from nearby regions lacking fluorescence. For each cell, measure DSBT as the 
ratio of corrected measures obtained in the YFP channel to those obtained in the CFP 
channel. DSBT measures are used to derive the correction factor B (Box 1), which is 
defined as the fraction of the signal in the acceptor channel that results from the 
bleedthrough of the mTurquoise emission.

15| *Collect images for measurement of fractional excitation of mVenus at 810 nm.* Using the 
same wavelengths, collect images of living cells expressing both mTurquoise and 
mVenus under conditions of minimal FRET (e.g., a mixture of the two, or a low-FRET
standard, from step 8) first with illumination at 810 nm, and then again using illumination at 960 nm. Laser power at 960 nm should be adjusted to be equivalent to that used at 810 nm, as measured with a laser power meter at the specimen plane.

**Troubleshooting**

**CRITICAL STEP:** Tuning a titanium-sapphire laser to different wavelengths may lead to differences in laser alignment that can impact quantitative measures. It is critical to ensure that laser alignment is unaffected, or corrected, when changing between 810 and 960 nm.

16] **Image analysis for measuring fractional excitation of mVenus at 810 nm.** Using image-processing software (e.g., ImageJ, Metamorph or the microscope manufacturer’s software), identify regions-of-interest in several cells expressing mVenus and for each region measure the signal levels in the YFP channels when excited at 810 nm and when excited at 960 nm. Correct these measurements for background by subtracting measurements obtained from nearby regions lacking fluorescence. For each cell, measure the ratio of corrected signals obtained at 810 nm illumination to those measured at 960 nm. This ratio is used, along with ASBT, to derive the correction factor A. The corrected FRET signal (FRET$_{corr}$) is determined by subtracting the crosstalk components A and B from the raw FRET signal (donor excitation, acceptor emission (Box 1)).

**System validation - Measure FRET in living cells expressing FRET-standard constructs – 3-4 hrs**

**CRITICAL:** The performance of the system is validated by measurement of FRET in cultured cells expressing the fully characterized FRET standard constructs. The determination of $E_{FRET}$ for the known FRET standards enables the user to assess the performance of their system, and
to compare their results with those obtained here (or from other studies if different standards are used). To ensure that physiological measurements are not compromised by potential changes in the laser, optics, or detectors, data should be collected for FRET standards with each physiological study.

17| **Image collection for measurements of FRET standards.** 24 - 48 h prior to imaging, transfec
HEK293 cells (as described in Steps 1-8) with the FRET standard constructs - mTurquoise-TRAF-mVenus, mTurquoise-5AA-Venus, mTurquoise-10AA-Venus and a 1:1 mixture of mTurquoise and mVenus (see step 4).

18| Prepare the TPLSM system for imaging, as described in Step 9.

19| Transfer transfected cells into a medium suitable for maintaining physiological pH in air, or into a chamber capable of maintaining 5% (vol/vol) CO₂ environment. Mount cells in a stage incubator set to maintain cells at 37 degrees C. ⚠ Troubleshooting

20| Using the same laser power and emission wavelength settings used in steps 12 and 15, collect two-channel images of cells expressing each of the FRET standard constructs and cells co-expressing mTurquoise and mVenus (see step 4).

**CRITICAL STEP:** Transient co-transfection of cells with a mixture of the mTurquoise and mVenus plasmids will produce highly variable relative expression levels of the two different FPs. For this protocol, it is important to pre-select cells for imaging that have intensity levels in both channels that are similar to the low FRET efficiency standard (mTurquoise-TRAF-mVenus, which has a fixed 1:1 ratio of the donor and acceptor with little donor quenching).
21| **Image analysis for measurements of FRET standards.** Using image-processing software, identify regions-of-interest in several cells expressing fluorescent proteins and for each region measure the signal levels in the CFP and YFP channels. Correct these measurements for background by subtracting measurements obtained from nearby regions lacking fluorescence. For each cell, measure the FRET ratio and calculate $E_{\text{FRET}}$ (Box 1).

**CRITICAL STEP:** The 2PE method described here should readily distinguish the three FRET standards with the different linker lengths from one another based on the measured $E_{\text{FRET}}$ (see **ANTICIPATED RESULTS**). It is critical to use this approach to demonstrate that the TPLSM system is properly set up to obtain accurate measurements of $E_{\text{FRET}}$, and is capable of high sensitivity measurements from the biosensor probes in living cells.

**Validate the FRET biosensor - Measure the biosensor probe FRET response in cultured cells - 5 hrs**

CRITICAL: It is important to validate the performance of the biosensor in a cell model prior to studies in more complex systems. The response of the biosensor probe is evaluated in living cells following treatment with agents known to stimulate the relevant physiological response pathway. Here, the PKA agonist forskolin (Fsk) is used to test the response of the AKAR4.1 biosensor to PKA activation.

22| **Image collection for measurements of FRET biosensor responses.** 24 - 48 h prior to imaging, transfect HEK293 cells with the FRET biosensor (here, AKAR4.1) as described in steps 1-8.
23| Prepare the TPLSM system for imaging, as described in Step 9.

24| Transfer transfected cells into a medium suitable for maintaining physiological pH in air, or into a chamber capable of maintaining 5% (vol/vol) CO2 environment. Mount cells in a stage incubator set to maintain cells at 37 degrees C.  ? Troubleshooting

25| Using laser power and emission wavelength settings used in steps 12, 15 and 17, collect a series of two-channel images of a field of cells expressing AKAR4.1 to establish baseline measurements.

26| Collect a series of images before and after activating the biosensor probe. Here, images were collected at 30 sec intervals before and after addition of Fsk to the culture medium (final concentration of 24 μM). Fsk-mediated activation of PKA is expected to induce a rapid and significant increase in the Venus to Turquoise emission ratio (see ANTICIPATED RESULTS).

27| Image analysis for measurements of FRET biosensor responses. Using image-processing software, identify regions-of-interest in several cells expressing AKAR4.1 and for each region measure the signal levels in the CFP and YFP channels. Correct these measurements for background by subtracting measurements obtained from nearby regions lacking fluorescence. For each cell at each time point, measure the normalized Venus to Turquoise emission ratio.

CRITICAL STEP: It is important to verify the function of the FRET-based biosensor probes using other methods, such as fluorescence lifetime imaging microscopy or acceptor photobleaching measurements. Additionally, it is important to demonstrate that the biosensor is reporting the correct cellular activity. Treatment of cells with unrelated signaling molecules, or
antagonists to the specific cellular pathway should not elicit the biosensor response. Moreover, point mutations in the bioactive linker (phosphorylation or binding sites) should abolish the changes in the probe response.

**Measure the biosensor probe FRET response in the organ of a living animal – Intravital microscopy - 7 hrs**

CRITICAL: Once the biosensor has been validated, the 2PE ratiometric method can be used to measure biosensor probe activity in the targeted organ in a living animal. Here, we demonstrate the approach by measuring the effect of glucagon on PKA activity in cells in the intact mouse liver in mice transduced with the Ad AKAR4.1 vector.

28| **Transduction of mice with a FRET biosensor.** 7 days prior to imaging, introduce 0.2 ml of the Ad AKAR4.1 vector (4.8 x 10^{10} particles) into mice by tail vein injection, using standard methods (e.g., http://www.procedureswithcare.org.uk/intravenous-injection-in-the-mouse/).

**Caution!** – All animal studies must be approved by the Institutional Animal Care and Use Committee and must conform to the National regulations. Studies of animals transduced with adenovirus must be conducted in compliance with institutional biosafety standards.

29| **Image collection of FRET biosensor responses in the liver of a living mouse.** Physiological manipulations and animal preparations will vary according to the study. To prepare for activation of PKA in liver via glucagon\textsuperscript{53}, withdraw food from mice 3 h prior to scheduled imaging.
30| Prepare the TPLSM system for imaging, as described in Step 9.

31| Externalize the left lateral lobe of the liver and prepare for IVM imaging through a glass bottom plate using methods previously described\textsuperscript{24}.

32| Place the animal on the warmed microscope stage, identify a field of hepatocytes expressing AKAR4.1 and, using the same microscope settings used in steps 12, 15, 17 and 26, collect a series of 3D image volumes (10 planes spanning 10 microns) in CFP and YFP channels to establish the baseline ratio. 3D stacks are collected to ensure sequential capture of hepatocyte cytosols despite residual vertical motion of the liver because of respiration.

33| Continue to collect 3D image volumes during and following IP injection of glucagon (200 μg/kg) to monitor the increase in the FRET ratio resulting from activation in PKA.

34| *Image analysis of FRET biosensor responses in the liver of a living mouse.* Using image-processing software, align and assemble image stacks into a sum of all planes for each channel and each time point.

35| Identify regions-of-interest in several cells expressing AKAR4.1 that display relatively uniform fluorescence. For each region measure the signal levels in the CFP and YFP channels. Correct these measurements for background by subtracting measurements obtained from nearby regions lacking fluorescence. For each cell at each time point, measure the Venus to Turquoise emission ratio.

36| Pool and normalize the measured emission ratio data for all regions of interest. ?

*Troubleshooting*

**TROUBLESHOOTING**
Troubleshooting advice can be found in Table 2.

TIMING [Note from editor: please update and correct step numbers in section below to reflect changes to the Procedure]

Steps 1-8, Cell transfection: ~ 1 h, approximately 24 - 48 h prior to imaging

Steps 9-10, Prepare TPLSM system for imaging: ~ 0.5 h

Optional Step 11, Determine the spectra ranges of the detector channels; ~ 1 h

Steps 12, Image collection for measurement of SBT: ~ 1 h.

Steps 13-14, Image analysis for measurement of SBT: ~ 1 h.

Step 15, Image collection for measurement of fractional excitation of mVenus at 810 nm: ~ 1 h

Step 16, Image analysis for measurement of fractional excitation of mVenus at 810 nm: ~ 1 h

Steps 17-20, Image collection for measurement of FRET standards in cultured cells: ~ 2 h

Step 21, Image analysis for measurement of FRET standards in cultured cells: ~ 4 h

Steps 22-26, Image collection for measurement of FRET biosensor responses in cultured cells: ~ 2 h

Step 27, Image analysis for measurement of FRET biosensor responses in cultured cells: ~ 3 h

Step 28, Transduction of mice with a FRET biosensor: ~ 1 h

Steps 29-33, Image collection for measurement of FRET biosensor responses in living mouse: ~ 4 h

Steps 34-36, Image analysis for measurement of FRET biosensor responses in living mouse: ~ 4 h

Box 1, Analysis of spectral bleedthrough for the determination of FRET efficiency: ~ 1 h

ANTICIPATED RESULTS
Measurements of the FRET standards using 2PE. The FRET standards are used to demonstrate that the experimental model and microscope system are optimized for sensitive measurements of $E_{\text{FRET}}$ in living cells (Steps 17-21). If the SBT corrections are accurate (Box 1), then there should be very little energy transfer detected in cells that express a mixture of the unlinked mTurquoise and mVenus. The low FRET-efficiency standard, mTurquoise-TRAF-mVenus should also have a low, but measurable $E_{\text{FRET}}$ ($\sim$5%)\textsuperscript{33,46,52}. In contrast, measurements from the cells expressing the highest $E_{\text{FRET}}$ standard, mTurquoise-5AA-Venus produce $E_{\text{FRET}}$ of about 45%. Critically, measurements from cells expressing the mTurquoise-10AA-Venus standard are expected to be about 36%, and should be readily distinguishable from the FRET standard with the shorter linker (Figure 4). These FRET standards allow the validation of the imaging system, and provide a clear indication of the sensitivity of the measurements. The FRET standards also provide a control for identifying changes in performance of the laser, optics, or detectors that may compromise measurements under physiological conditions.

2PE measurements of FRET-based biosensor probe activities in cultured cells. Biosensor validation is accomplished in studies in cultured cells expressing the biosensor that are treated with established methods to activate the cell-signaling event. For our studies, we transfected HEK293 cells with AKAR4.1 and monitored emissions in the cyan (454 – 494 nm) and yellow (520 – 580 nm) channels under illumination at 810 nm (Step 22-27). After collecting a series of baseline images, the PKA agonist forskolin (Fsk) was added to a final concentration of 24 $\mu$M. As expected, forskolin induced a rapid and pronounced (1.4-fold) increase in the emission ratio of Ven/Turq (Figure 5).

2PE measurements of FRET-based biosensor probe activities in living animals. After validation of the microscope system and the biosensor, studies are next conducted in living
animals. For our studies, we took advantage of the robust tropism of adenovirus for the mouse liver following tail vein injection\textsuperscript{20} (Step 28). Seven days after injection with Ad AKAR4.1, the mice were fasted for 3 h, prepared for IVM and then imaged as described above (Steps 29-33). Baseline images were collected, and imaging was continued after IP injection of glucagon (200 μg/kg), a treatment that has been previously shown to rapidly stimulate both cAMP and PKA in hepatocytes of fasted mice\textsuperscript{53}. Similar to the results obtained with HEK-293 cells treated with Fsk, glucagon treatment in the living mouse induced a rapid 1.4 fold change in emission ratio of Ven/Turq (\textbf{Figure 6}), indicating a rapid and sustained activation of PKA. A certain degree of cell-cell variability can be expected from cells in vivo; our earlier measurements\textsuperscript{33} of 32 hepatocytes, from three separate studies ranged from 1.14 to 1.827.

\textit{Note: Any Supplementary Information and Source Data files are available in the online version of the paper.}

\section*{ACKNOWLEDGMENTS}

This research is supported by the National Institutes of Health O’Brien Center for Advanced Renal Microscopic Analysis (NIH-NIDDK P30DK079312). The authors thank Dr. Malgorzata Kamocka and Seth Winfree for their assistance in microscopy. This paper is dedicated to the memory of Michael W. Davidson.

\section*{AUTHOR CONTRIBUTIONS}

R.N.D. and K.W.D. wrote the manuscript. W.T. conducted the experiments, and R.N.D and K.W.D. supervised the research. Author RND is a leading expert in the field of fluorescent
protein biosensors. Author KWD is one of the pioneers of intravital imaging in living animals using TPLSM.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.
Box 1: Analysis of spectral bleedthrough for the determination of FRET efficiency.

Digital Image Analysis - Timing ~ 1.5 h

The optical pathway of the microscope system must be optimized for the detection of the mTurquoise-mVenus based biosensor probe when excited at 810 nm. This is achieved by imaging cells that express either mTurquoise or mVenus alone (Procedure Steps 12-14). Spectral scanning on systems with spectral detectors, or careful selection of emission filters on filter-based systems will allow the user to adjust the optimal bandwidth for detection of the donor and acceptor signals (Procedure step 11). Once the donor and acceptor emission bandwidths are set, it is then necessary to measure the contributions of spectral bleedthrough (SBT) to the signals detected in the FRET channel (excitation 810 nm, acceptor emission). The subtraction of the SBT signals from the signal that is detected in the FRET channel (FRETraw) provides the corrected FRET (FRETcorr) signal:

\[ \text{FRET}_{\text{corr}} = \text{I}_{\text{FRET}} - A \times \text{I}_{\text{FRET}} - B \times \text{I}_{\text{Turq}} \]  

(Eq 1)

Correction for acceptor spectral bleedthrough (ASBT): The ASBT signal arises from the direct excitation of mVenus at 810 nm. The correction factor A (Eq 1) is used to remove ASBT. Measurements from cells expressing only mVenus are obtained using both 810 nm and 960 nm excitation to determine the fraction of the acceptor signal that arises from the direct excitation of mVenus at 810 nm. For our system, we determined that the ASBT fraction was 0.030. Because this protocol uses a single excitation wavelength (810 nm) to measure FRET standard and biosensor activity, it is also necessary to approximate the intensity in the acceptor channel (Ch2-960) from the measurement at 810 nm (i.e., the fractional excitation of Venus at 810 nm). This is accomplished by measuring the average...
ICh2-810/ICh2-960 ratio from cells expressing a mixture of mTurquoise and mVenus, and cells expressing the low-FRET standard (Turquoise-TRAF-Venus). For our system the average ratio was 0.344. Therefore, multiplication of the acceptor intensity measured with excitation at 810 nm by 2.91 (1/0.344) provides an approximation of the intensity in the acceptor channel to allow correction for ASBT. For our microscope system, the correction factor A is 2.91 x 0.03 = 0.087.

**Correction for donor spectral bleedthrough (DSBT):** The correction factor B (Eq 1) is used to remove DSBT, the signal detected in the acceptor channel that results from donor emission bleedthrough, and is determined from cells expressing only mTurquoise. Measurements from the donor-alone cells excited at 810 nm allowed us to determine the donor bleedthrough fraction was 0.295 on our system. Thus, the FRETcorr can be determined by:

\[ 2\text{PE} \text{FRET}_{\text{corr}} = I_{\text{FRET}} - 0.087*I_{\text{FRET}} - 0.295*I_{\text{Turq}} \quad \text{(Eq 2)} \]

**Determining FRET efficiency (E_{FRET}) for the FRET standards:** The validation of the imaging system is accomplished by measurement of the FRET standards. Here, measurements are acquired from cells expressing a low E_{FRET} standard (mTurquoise-TRAF-mVenus), and two high E_{FRET} standards (mTurquoise-5AA-Venus and mTurquoise-10AA-Venus) as described in **ANTICIPATED RESULTS**. The low E_{FRET} standard provides an indication of the threshold of detection, while the measurements from the two different high E_{FRET} standards allow the user to assess the sensitivity of the system.

The E_{FRET} is calculated as previously described\textsuperscript{33,50,51} using the equation:
\[ E = \frac{D_{\text{lost}}}{D_{\text{total}}} = \frac{D_{\text{lost}}}{(D_{\text{lost}} + D_{\text{remains}})} \quad (\text{Eq 3}) \]

Where

\[ D_{\text{lost}} = \text{FRET}_{\text{corr}} \cdot (QY_d / QY_a) \cdot (S_d / S_a) \cdot (G_d / G_a) \quad (\text{Eq 4}) \]

and

\[ D_{\text{remains}} = I_{\text{Turq-810}} \quad (\text{Eq 5}) \]

QY\textsubscript{d} and QY\textsubscript{a} denote the quantum yields of the donor and acceptor, respectively, where the quantum yield ratio for mTurquoise and mVenus is 1.474\textsuperscript{35,40}. S\textsubscript{d} and S\textsubscript{a} denote the spectral sensitivities of the donor and acceptor channels. The S\textsubscript{d} / S\textsubscript{a} ratio is approximated by the bandwidth ratio of channel 1 and channel 2. G\textsubscript{d} and G\textsubscript{a} are the detector gains for the donor and acceptor emission channels, and were set to a scaling factor of 1 for all measurements.

END OF BOX 1
### Table 2: Troubleshooting table.

<table>
<thead>
<tr>
<th>Step</th>
<th>Problem</th>
<th>Possible reason</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12, 15, 17, 22</td>
<td>Cells do not adhere to the cover slip properly, or they are not healthy</td>
<td>Cover slips are not coated with appropriate matrix. Inappropriate culture conditions</td>
<td>Coat cover slips with poly-d-lysine or collagen. Ensure that the culture conditions are optimized for the cell line used.</td>
</tr>
<tr>
<td>12, 15, 17, 22</td>
<td>Inadequate expression of fluorescent proteins in cultured cells</td>
<td>The transfection agent (FuGENE, Lipofectamine, X-tremGene HP) or DNA plasmid concentration or their ratio is not optimized</td>
<td>Follow the transfection agent manufacturer’s recommendations to vary the ratio of DNA: transfection agent or concentrations of DNA and/or transfection agent.</td>
</tr>
<tr>
<td>12, 15, 17, 22, 29</td>
<td>Photobleaching is observed</td>
<td>The power of the excitation light is too high</td>
<td>Optimize the optical path and/or reduce laser power.</td>
</tr>
<tr>
<td>12, 15, 17, 22, 29</td>
<td>The signal fluctuates during TPLSM data acquisition</td>
<td>The laser illumination is unstable.</td>
<td>Ensure that laser is warmed for ~30 min prior to imaging. Ensure that room temperature is stable.</td>
</tr>
<tr>
<td>17, 22, 29</td>
<td>FRET measurements are obscured and/or altered by cell or tissue autofluorescence.</td>
<td>Components in the specimen have fluorescence excitation properties at the donor 2PE wavelength.</td>
<td>Avoid media with indicator dyes. Change range of spectral detector or change bandpass filter for acceptor and/or donor emissions to minimize interference. Collect images from FRET standards expressed in the same cells or tissues used in studies of physiology.</td>
</tr>
<tr>
<td>11</td>
<td>Substantial bleedthrough of the acceptor signal in the donor channel is observed.</td>
<td>Spectral bandwidth of donor channel extends too far into the range of the acceptor emissions. Spectral bandwidth of acceptor channel is too wide or inappropriate dichroic mirror used.</td>
<td>Change range of spectral detector or change bandpass filter for acceptor and/or donor emissions.</td>
</tr>
<tr>
<td>11</td>
<td>Substantial bleedthrough of the donor signal into the acceptor channel.</td>
<td>Spectral bandwidth of acceptor channel extends too far into the range of the</td>
<td>Change range of spectral detector or change bandpass filter for acceptor</td>
</tr>
<tr>
<td>Cause</td>
<td>Effect</td>
<td>Solution</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Excessively high value of correction factor “B”.</td>
<td>donor emissions or inappropriate dichroic mirror used.</td>
<td>and/or donor emissions.</td>
<td></td>
</tr>
<tr>
<td>21 Spatial variation in ratios measured for the FRET standards</td>
<td>Chromatic aberration</td>
<td>Choose chromatically corrected optical components.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Variable illumination across the field</td>
<td>Ensure homogeneous illumination; restrict measurements to homogenous region.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Variable background across the field</td>
<td>Use local background subtraction for quantifications.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Spatial variation in photobleaching.</td>
<td>Minimize illumination levels, minimize time spent identifying fields to collect.</td>
<td></td>
</tr>
<tr>
<td>21 FRET standards fail to produce the expected $E_{FRET}$.</td>
<td>Low levels of probe expression resulting in high background contributions, errors in image processing, or errors in SBT corrections.</td>
<td>It is critical to verify the FRET measurements of the standards by multiple methods (e.g., sensitized emission, acceptor photobleaching, fluorescence lifetime)(^{33}). The different methods should provide the same $E_{FRET}$ for the standards.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deterioration of TPLSM system performance.</td>
<td>If comparison with previous studies indicates a decline in the imaging system performance, check the optical path for alignment issues, check all filter settings, and measure laser power at the specimen plane to verify that it is the same as previous studies. If this fails, call for microscope service.</td>
<td></td>
</tr>
<tr>
<td>26, 27 Biosensor fails to respond Cells are not healthy.</td>
<td>Cells are not healthy.</td>
<td>Ensure that cells are</td>
<td></td>
</tr>
<tr>
<td></td>
<td>as expected to physiological stimulation.</td>
<td>Probe activator is ineffective.</td>
<td>healthy (see steps 1-2). Ensure that probe activator is fresh, appropriately handled and used at the correct concentration. If comparison with previous studies indicates a decline in the imaging system performance, check the optical path for alignment issues, check all filter settings, and measure laser power at the specimen plane to verify that it is the same as previous studies. If this fails, call for microscope service.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Deterioration of TPLSM system performance.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

|   | 29, 36 Fluorescence image decreases in intensity and/or clarity over time. | Water has evaporated from water immersion objective. | Replenish water more frequently. Consider switching to oil, glycerol or silicon-oil immersion objectives. |
REFERENCES


FIGURE LEGENDS

Figure 1| Schematic overview of the Procedure to measure biosensor activity in the living animal. Following viral transduction of a biosensor probe in mice, the procedure is used to monitor the activity of the probe in the anesthetized animal. The procedure uses selective 2PE of mTurquoise at 810 nm to make ratiometric FRET measurements in vivo. To image probe activity in the liver, the left lateral lobe of the liver was carefully lifted and secured to a glass bottom plate. The mouse is then placed ventral side down on a heated microscope stage and covered with a warming blanket, and the liver is imaged using a long working-distance water-immersion objective.

Figure 2| Diagram of the flow of the Procedure. The Procedure starts with transfection of cells (Procedure steps 1-8) with a series of standards that are used to evaluate and optimize the TPLSM system, and to determine the SBT components when using 2PE at 810 nm (Procedure steps 10-16). Then, the FRET standards are used to evaluate the sensitivity of the system for the accurate measurement of $E_{\text{FRET}}$ (Procedure steps 17-21). The biosensor probe of interest is then verified in a cell model by measuring changes in the Venus to Turquoise ratio over time in response to suitable activators of the targeted signaling pathway (Procedure steps 22-27). Once the system and biosensor have been verified, studies in the living animal are conducted (Procedure steps 28-36).

Figure 3| 2PE spectral scanning of the indicated FPs expressed individually in living HEK-293 cells. The relative 2PE spectral scans for (a) mTurquoise and (b) mVenus, were acquired from living cells by measuring fluorescence emissions over a range of excitation wavelengths at
a constant laser power and a detector scaling factor of 1; the red bar indicates excitation at 810 nm used in this protocol. In order to provide fluorescence excitation spectra that are independent of variations at the output of the laser at different wavelengths, spectral variation in laser power was eliminated by adjusting laser power to a constant value at each wavelength, as measured using a PM100D power meter with correction (Thorlabs, Newton, NJ), mounted on the microscope stage\textsuperscript{33}. The emission signals at the different excitation wavelengths were simultaneously detected in channel 1 (cyan, 454 – 494 nm) and channel 2 (yellow, 520 – 580 nm), and the images are acquired at each wavelength step as described in the Experimental Design. [Adapted from ref 33]

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{FRET ratio images of HEK-293 cells expressing the indicated FRET standard probes. Cells were excited by illumination at 810 nm and the mTurquoise (donor) intensity was measured in channel 1 (454 – 494 nm), while mVenus (acceptor) intensity was measured in channel 2 (520 – 580 nm). The FRET ratio images obtained from representative cells expressing the different FRET standard fusion proteins are shown (scale bar is 10 μm). [Adapted from ref 33]}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{Ratiometric FRET measurements from HEK-293 cells expressing the AKAR4.1 biosensor probe. The cells are illuminated at 810 nm and the emission signals are simultaneously measured in the mTurquoise (donor) channel (454 – 494 nm) and the mVenus (acceptor) channel (520 – 580 nm). The cells were treated with protein kinase A (PKA) activator Forskolin (Fsk) to elicit changes in the FRET signal from the AKAR4.1 biosensor}
\end{figure}
probe. (a) FRET ratio images of cells prior to (pre-treatment) and 3 min after Fsk treatment (scale bar is 10 μm). (b) The cells were treated with Forskolin (Fsk) at time zero and the acceptor to donor ratio (Ven/Turq) was measured every thirty seconds for ten minutes. The Ven/Turq ratio was determined from eleven cells (± SE) as described in Box 1. [Adapted from ref 33]

Figure 6 | Using TPLSM to measure the response of the AKAR4.1 biosensor to glucagon in hepatocytes in the intact mouse liver. The Ad AKAR4.1 viral particles were introduced by tail vein injection, and resulted in extensive expression in the liver 7 days later. (a) Ratio images from a single image plane in mouse liver at the indicated time points (scale bar is 10 μm). (b) The mouse was treated by IP injection with glucagon (200 μg/kg) at time zero and the acceptor to donor ratio (Ven/Turq) was measured every fifteen seconds for ten minutes. The Ven/Turq ratio was determined as described in Box 1, and the results are from the 10 individual cells (± SE). [Adapted from ref 33] All animal studies were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee and conform to the “Guide for the Care and Use of Laboratory Animals” published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996).

Supplementary Information

Supplementary Sequence Archive. DNA sequence information for plasmids used in this protocol (see Table 1).
Figure 1.
Figure 3.
Figure 5.
Figure 6.